PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SARCOMA, EXPERIMENTAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,441 records · Page 80Linked to original sources

ABROGATION OF ALLOGENEIC INHIBITION BY CORTISONE.

Tumor cells from homozygous mice grow better upon transplanation to syngeneic mice than to F(1) hybrids between the tumor strain and a foreign strain. The inhibition of cell growth in the hybrids (called allogeneic inhibition), which is detected by tumor transplantation into mice, cotuld be abrogated by treatment of the recipient mice with cortisone acetate. Cortisone also abolished allogeneic inhibition in vitro; abolition was detected by treating tumor cultures with cell extracts containing foreign isoantigens of the H-2 type.

Animals↗

Antitumor tests of amygdalin in transplantable animal tumor systems.

Except for oral administration, there was no grossly observed toxicity from carefully administered high doses of amygdalin in the experimental systems used. The compound in high doses was ineffective against the DMBA-induced rat mammary carcinoma and the following transplanted experimental tumors: Sarcoma 180, plasma cell tumor LPC-1, leukemia L1210, Mecca lymphosarcoma, Ridgway osteogenic sarcoma, sarcoma T241, mammary carcinoma E0771, Taper liver tumor, Ehrlich carcinoma (solid and ascites), and Walker carcinosarcoma 256. Amygdalin did not noticeably influence the toxicity or impair the efficacy of these chemotherapeutic agents in their respective systems: Cytosine arabinoside, methotrexate, cytoxan, or 5-fluorouracil in L1210; the latter two in LPC-1; 6-mercaptopurine in Ridgway osteogenic sarcoma; estradiol-17beta or 2alpha-methyldihydrotestosterone propionate in the DMBA-induced rat mammary carcinoma.

Amygdalin↗